RxDoctor Payments Data

Mary Buck

Nurse Practitioner · Savannah, GANPI 1871665208

Payments from drug & device makers

$3,158in general payments, 2019–2025

Across 168 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$436
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
  • QOL Medical, LLC$233
  • Bristol Myers Squibb$152
  • Redhill Biopharma Inc.$100
  • plus $354 from 11 others

What the payments were for

  • Food & beverage$3,05997%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,158 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$77,403
Medicare patients
619
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide99$90,884
XifaxanRifaximin18$49,545
MotegrityPrucalopride Succinate37$21,287
TrulancePlecanatide22$12,961
Mesalamine19$10,626
Colesevelam Hcl83$9,448
Dexlansoprazole DrDexlansoprazole29$9,121
Pantoprazole Sodium391$5,818
Omeprazole330$4,797
Colestipol Hcl29$3,429
Dicyclomine Hcl212$3,069
Famotidine213$2,850
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates39$2,763
Esomeprazole Magnesium67$2,285
Sucralfate61$1,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,616$90,88499 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$267$62,50640 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$19$21,28737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →